Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00206648 · ClinicalTrials.gov registry record · Phase 4

An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS

A Phase 4 study of Multiple Sclerosis (Relapsing Remitting), sponsored by Bayer.

Completed
Registry status
Phase 4
Development phase
271
Enrollment target
20
Study locations

NCT00206648 is a Phase 4 study of Multiple Sclerosis (Relapsing Remitting) that has completed, run by Bayer. The registered enrollment target is 271 participants, below the 553-participant average among 29 other Multiple Sclerosis (Relapsing Remitting) trials with a reported enrollment target (51% lower). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00206648, a Phase 4 study of Multiple Sclerosis (Relapsing Remitting), has completed, sponsored by Bayer.

COMPLETED
Registry status
Phase 4
Development phase
271 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to determine the difference in preventing a relapse between Betaseron and Avonex. Patients with RRMS currently treated with Avonex will be randomized into 2 equal-size arms; one arm will continue on the standard dose of Avonex; one arm will be converted to Betaseron standard dose.

Conditions Studied

Multiple Sclerosis (Relapsing Remitting)

Interventions

  • DRUG Betaferon/Betaseron

Study Locations (20)

California

  • - Berkeley
  • - Irvine
  • - Loma Linda
  • - Los Angeles
  • - Sacramento
  • - San Jose
  • - Walnut Creek
  • - Walnut Creek

Florida

  • - Melbourne
  • - Miami
  • - Tampa
  • - Tampa

Georgia

  • - Atlanta
  • - Augusta
  • - Columbus
  • - Savannah

Illinois

  • - Flossmoor
  • - Springfield

Arizona

  • - Tucson

Delaware

  • - Wilmington

Trial Details

FieldValue
Enrollment Target 271 participants
Start Date 2003-03
Est. Completion 2005-10
Phase Phase 4

Sponsor

Bayer

591 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00206648

The ClinicalTrials.gov registry entry for NCT00206648 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 271 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 553-participant average among 29 other Multiple Sclerosis (Relapsing Remitting) trials with a reported enrollment target (51% lower). The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Sclerosis (Relapsing Remitting) appearing as the primary indexed condition, and to 1 intervention - of which Betaferon/Betaseron is the first listed.

NCT00206648 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT00206648 about?

NCT00206648 is a clinical study titled "An Efficacy and Safety Comparison Study of Two Marketed Drugs in Patients With Relapsing-remitting MS". The purpose of this study is to determine the difference in preventing a relapse between Betaseron and Avonex. Patients with RRMS currently treated with Avonex will be randomized into 2 equal-size arms; one arm will continue on the standard dose of Avonex; one arm will be converted to Betaseron stan...

What is the current status of trial NCT00206648?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 271 participants. The study started on 2003-03. Estimated completion is 2005-10.

What conditions does trial NCT00206648 study?

This clinical trial studies the following conditions: Multiple Sclerosis (Relapsing Remitting).

What interventions are being tested in trial NCT00206648?

The interventions under investigation include: Betaferon/Betaseron (DRUG).

Who is sponsoring clinical trial NCT00206648?

This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00206648 being conducted?

This trial has 20 study locations across Arizona, California, Delaware, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Sclerosis (Relapsing Remitting)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Sclerosis (Relapsing Remitting)

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.